AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02988596 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Graded Exertion
Description: Participants will be asked to use their symptoms to guide their activity from the time of their injury until they are asymptomatic. Once they are asymptomatic they will begin the graded exertion (Zurich/Berlin Protocol). During this time clinicians will complete session logs that include the following information: initial symptom checklist, phase of graded return to play progression, activity parameters, percentage of rest during the session, participants rating of perceived exertion, and final symptom checklist, session satisfaction rating, and session feedback.
Study NCT01335789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 40 IUs
Study NCT01335789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 40 IUs
Study NCT05695573 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ACR, fasting, postprandial blood glucose ,HbA1c, creatinine, cystatin-C, BUN, Na, K , lipid profile
Description: Use the ACR to divide diabetic patients to 3groups not normoalbuminuria, microalbuminuria, macroalbuminuria to evaluate the urinary uromodulin level and its exosomal umod mRNA as a potential biomarker of Diabetic nephropathy diagnosis
Study NCT01283646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apevitin BC
Description: 3.5 to 5 ml 3 times a daily
Study NCT01283646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B Complex + Vitamin C
Description: 3.5 to 5 ml 3 times a daily
Study NCT03980210 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Description: 1. FiO2 0.21 - 1 ATA~2. FiO2 1 - 1 ATA~3. FiO2 1 - 2.5 ATA~4. FiO2 0.21 - 2.5 ATA~5. FiO2 0.21 - 1 ATA
Study NCT00849147 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haploidentical Bone Marrow Transplantation
Description: The transplant preparative regimen is listed below. The - sign is the number of days before the transplant.~* Fludarabine: 30 mg/m2 intravenously (IV) on Days -6, -5, -4, -3, and -2~* Cyclophosphamide (Cy): 14.5 mg/kg IV on Days -6 and -5~* Total body irradiation (TBI): 200 centigray (cGy) on Day -1~Day 0 is the day of the infusion of non-T-cell depleted bone marrow. The bone marrow will be obtained from haploidentical related donor.
Study NCT00849147 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVHD prophylaxis
Description: The GVHD prophylaxis regimen will consist of the following:~* Cy: 50 mg/kg IV on Days 3 and 4~* Tacrolimus: (IV or orally) beginning on Day 5 with dose adjusted to maintain a level of 5 to 15 mg/mL~* Mycophenolate mofetil (MMF): 15 mg/kg orally three times a day (TID) beginning on Day 5; maximum dose will be 1 g orally TID~* Granulocyte-colony stimulating factor (G-CSF) 5 mcg/kg/day beginning on Day 5 until absolute neutrophil count (ANC) is greater than or equal to 1,000/mm\^3 for 3 consecutive days
Study NCT00533039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varespladib (A-002)
Description: 250mg tablets BID for 3-5 days pre-angioplasty and 5 days post-angioplasty.
Study NCT00533039 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 250mg tablets BID 3-5 days pre-angioplasty and 5 days post-angioplasty.
Study NCT01668342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS assessments & feedback
Description: Daily symptom assessments tied to tailored feedback
Study NCT04672473 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-CTL
Description: DAC combined with Ag-CTL
Study NCT02157402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social marketing activities and pop-up events to promote healthy lifestyles
Study NCT01364519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: Dry powder for inhalation, Single Dose, 500mcg
Study NCT01364519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Fluticasone Propionate
Description: Dry powder for inhalation, Single Dose, placebo
Study NCT01530009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: A liquid preparation of amoxicillin will be administered via a nasoduodenal catheter as a one time dose of 20 mg/kg.
Study NCT01530009 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A liquid placebo will be administered via nasoduodenal catheter to patients based on random assignment.
Study NCT02212717 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided gallbladder drainage (EGBD)
Description: The gallbladder would be identified by a linear echoendoscope (EUS) and a suitable puncture site in the stomach or the duodenum without intervening blood vessels would be located. The gallbladder would be punctured with a 19-gauge needle and a guidewire would be passed through the needle and looped in the gallbladder. The Hot AXIOS stent would then be inserted. A naso-gallbladder drain or a 5-7Fr double pigtail stents can be inserted into gallbladder if the effluent failed to clear after irrigation. This would be performed to improve drainage and avoid obstruction of the stent.
Study NCT02212717 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous cholecystostomy (PC)
Description: Trained interventional radiologists in the respective hospitals would perform the procedure under local anesthesia. A transhepatic route would be used in all patients to decrease bile leakage. An 8.5 Fr pigtail drainage catheter would be placed between the 8th or 9th intercostal space under sonographic and fluoroscopic guidance. The pigtail catheter would be drained to a bedside bag.
Study NCT03952988 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic ice cream
Description: One portion (50g) of an ice-cream containing the probiotic B. bifidum 900791 (>10(exp7)/g) every day for 4 weeks
Study NCT02680756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Maltol
Study NCT02680756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Carboxy Maltose
Study NCT03952988 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ice cream
Description: One portion (50g) of an ice-cream without probiotic every day for 4 weeks
Study NCT00277160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neulasta (pegfilgrastim)
Description: Commercial pegfilgrastim 6mg single subcutaneous fixed-dose
Study NCT00277160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neulasta (pegfilgrastim)
Description: Commercial pegfilgrastim 6mg single subcutaneous fixed-dose
Study NCT02389699 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative Radiotherapy
Description: Boost with 20 Gy during BCS, EBRT with 46-50 Gy
Study NCT02389699 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole breast radiation
Description: whole breast radiation after BCS with 46-50 Gy
Study NCT01235442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1=Etanercept
Description: 50 mg SC bi-weekly for 12 weeks followed by 50 mg SC weekly for 12 weeks.
Study NCT01235442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2=Clobetasol propionate foam
Description: 0.05% clobetasol propionate foam applied topically twice daily during two up-to-2 week courses
Study NCT04805619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biomime Morph, a tapered drug eluting stent (DES) with hybrid design
Description: Biomime Morph DES is a cobalt-chromium stent, with strut thickness of 65 µm, a hybrid cell design (closed cells in the extremity and open cells in the middle) and a conic shape, where the proximal part of the stent is 0.5 mm larger than the distal part (Table 1). In addition, the Biomime Morph elutes Sirolimus from a biodegradable polymer matrix.
Study NCT02430207 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: temporary pacing femoral vein
Description: Temporary pacing via femoral or subclavian vein
Study NCT02430207 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: temporary pacing subclavian vein
Study NCT03290521 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No washing
Description: no washing
Study NCT04586751 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pecs block
Description: Pecs block under real-time ultrasound guidance after anesthesia induction will be performed.
Study NCT04586751 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: no Pecs block
Description: no regional block will be performed in this arm
Study NCT03988062 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TrelliX Embolic Coil System
Description: Embolic coil with shape memory polymer
Study NCT04659343 — intervention group
Intervention type: OTHER
Intervention: Measurement of concentration of active metabolite in cancer treatment.
Description: Medical treatment for metastatic renal cell carcinoma with axitinib, cabozantinib, pazopanib, sorafenib, sunitinib, tivozanib, ipilimumab and nivolumab.
Study NCT00853684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXCE
Description: Oxaliplatin 130 mg/m2 iv drip D1, Capecitabine 1000 mg/m2 bid d1-14. Every three weeks.
Study NCT02805387 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Bicarbonate was ingested
Study NCT03377855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Default Prescribing Change
Description: In the e-prescribing system, the default opioid dosage/duration is changed to the minimum recommended dosage from the CDC guidelines for short acting opioids.
Study NCT03298464 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM313
Description: Subcutaneous injection
Study NCT03298464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: White to off-white round tablet
Study NCT01176799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm A
Description: Doxorubicin 60mg/m2 day 1 Cyclophosphamide 600mg/m2 day1, every 3 weeks x 4 cycles
Study NCT01176799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm B
Description: Days -13 (or -7) to day 0 (total 7 or 14 days) - oral sunitinib daily Cycle 1: day 1 - Cycle 1 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 2: day 1 - Cycle 2 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 3: day 1 - Cycle 3 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 4: day 1 - Cycle 4 AC (60/600mg/m2)
Study NCT02013037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: At the time of transplantation, 1200mg of Eculizumab will be administered via a 35 minute IV infusion, followed by thymoglobulin 1.5 mg/kg intravenous piggyback (IVPB). The administration of thymoglobulin will be repeated (if blood counts permit) for a total of five doses.~On Day 1 post-transplant, 900 mg of Eculizumab will be given via an IV infusion.~On Day 5 post-transplant, intravenous immunoglobulin (IVIG) 1 gram/kg will be administered daily for two consecutive days.~On post-transplant days 7, 14, and 21 (+/- 2 days) 900mg of Eculizumab will be given via an IV infusion at each scheduled visit.~On post-transplant days 28, 42, and 56 (+/- 2 days) 1200 mg of Eculizumab will be given via an IV infusion at each scheduled visit.
Study NCT01912001 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Telephone follow-up
Study NCT01912001 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sympton Assessment
Study NCT02094261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291
Description: Once daily tablet 80 mg
Study NCT04284553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Order Entry
Description: An alert will display in the electronic health record when the provider orders one of the high-risk medications for an eligible patient.
Study NCT04284553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open Encounter
Description: An alert will display in the electronic health record when the provider opens the chart of an eligible patient.
Study NCT03761654 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Global Longitudinal Strain measure
Description: Global Longitudinal Strain measure on day 1 of hospitalization
Study NCT02783157 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Low-Level Vagal Nerve Stimulation (LLVNS)
Description: Low-level vagal nerve stimulation will be delivered via a clip applied to the ear throughout the surgical procedure. The voltage used will be individualized to each patient, based upon the voltage necessary to slow the sinus rate during testing.
Study NCT02783157 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham LLVNS
Description: A clip will be applied to the ear, but no stimulation will be delivered throughout the procedure.
Study NCT00465985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885
Study NCT00465985 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00285558 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT with peer-enhanced activities
Study NCT00285558 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT with supervised aerobic exercise
Study NCT04284553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up booster Alert
Description: Once the order entry or open encounter alert displays, the provider will have the option to schedule a follow-up message that will be sent 4 weeks after the alert is triggered
Study NCT04284553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold State outreach
Description: An in-basket message will be sent to the eligible provider 2 days before the eligible patient is scheduled for an in-person visit.
Study NCT02165891 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: insertion of a chest drain with urokinase instillation
Description: Other interventions except drainage procedure are the same in both arms
Study NCT02165891 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: primary video-assisted thorascopic surgery
Study NCT00608348 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic glucose clamp procedures
Description: 2 hours of either euglycemic or hypoglycemic glucose clamping
Study NCT00608348 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: moderate exercise
Description: 90 minutes of moderate exercise with either hyperinsulinemia or euinsulinemia
Study NCT04417712 — intervention group
Intervention type: DEVICE
Intervention: KONAR-MF™ VSD Occluder
Description: All patients will be implanted with a KONAR-MF™ VSD Occluder in accordance with the instructions for use (IFU).
Study NCT02702921 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgeon's 'standard of care' stapler
Study NCT02702921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ethicon Powered Vascular Stapler
Study NCT03317353 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestibular rehabil.: CDP
Description: Vestibular rehabilitation, ten sessions
Study NCT03317353 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestibular rehabil.: optokinetic stimuli
Description: Vestibular rehabilitation, ten sessions
Study NCT03317353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular rehabil.: home exercises
Description: Exercises performed twice a day for two weeks. Approximate duration of each session: 15 minutes
Study NCT03302156 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PSMA-based 18F-DCFPyL PET tracer
Description: PSMA-based 18F-DCFPyL PET tracer that will be used to determine the presence or absence of cancer
Study NCT01701154 — intervention group
Intervention type: OTHER
Intervention: respiratory muscle strength training
Study NCT06138951 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Endurance exercise
Description: On the trial day before commencing the indicator amino acid oxidation metabolic trial, participants will either rest, perform a 10km run on a treadmill, or perform a 20km run on a treadmill.
Study NCT06138951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance exercise
Description: On the trial day before commencing the indicator amino acid oxidation metabolic trial, participants will either rest, perform a 10km run on a treadmill, or perform a 20km run on a treadmill.
Study NCT00399984 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma Education Program
Description: interactive seminars regarding daily inhaled corticosteroids
Study NCT00853684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: Endostar 7.5 mg/m2 iv drip D1-14. Every 3 weeks.
Study NCT00663156 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: breast implants
Description: patients will have breast augmentation using implants
Study NCT00663156 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction, fat grafting
Description: Autologous fat will be harvested from the body (typically the abdomen or thighs) using syringe aspiration techniques and then infiltrated into the subcutaneous tissue around the breast as well as between the breast and the underlying musculature using blunt cannulas. These procedures will be done in an outpatient surgery setting in the Georgetown University Hospital under general anesthesia and sterile conditions.
Study NCT00932607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sublingual immunotherapy
Description: Start with 1 drop daily of SUBLIVAC Birch and increase by 1 drop daily, until the maintenance dose of 5 drops is reached. This maintenance dose should then be taken daily. Or 1 puff of Staloral Birch 10 I.R./ml on day one, 2 puffs on day two and increase by 2 puffs until at day six 10 puffs are reached. At day seven 1 puff of Staloral Birch 300 I.R./ml is taken, at day eight 2 puffs and day nine 4 puffs. From then on 4 puffs daily are taken.~Route of administration: Sublingual application. Drops (for SUBLIVAC Birch) or puffs (for Staloral Birch) are to be held underneath the tongue and then will be swallowed.~Duration of treatment: 16-20 weeks per subject (at least 12 weeks for subjects with hazel or alder allergy).
Study NCT00932607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sublingual immunotherapy
Description: Start with 1 drop daily of SUBLIVAC Birch and increase by 1 drop daily, until the maintenance dose of 5 drops is reached. This maintenance dose should then be taken daily. Or 1 puff of Staloral Birch 10 I.R./ml on day one, 2 puffs on day two and increase by 2 puffs until at day six 10 puffs are reached. At day seven 1 puff of Staloral Birch 300 I.R./ml is taken, at day eight 2 puffs and day nine 4 puffs. From then on 4 puffs daily are taken.~Route of administration: Sublingual application. Drops (for SUBLIVAC Birch) or puffs (for Staloral Birch) are to be held underneath the tongue and then will be swallowed.~Duration of treatment: 16-20 weeks per subject (at least 12 weeks for subjects with hazel or alder allergy).
Study NCT04031417 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hypoxia
Study NCT04031417 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Low Humidity
Study NCT00343824 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: aquacel AG hydrofiber versus acticoat burn dressing
Description: Aquacel AG hydrofiber versus acticoat burn dressing will be compared.
Study NCT04284553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simplified
Description: The alert language itself will be simplified.
Study NCT04284553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sign-off alert
Description: An alert will display in the electronic health record when the medication is sent to sign-off for providers.
Study NCT04284553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-commitment
Description: A two-staged pre-commitment electronic health record alert will be used. In the 1st alert, the providers will be prompted to discuss risks of these high-risk medications and share a handout about the risks with their patients, at their own discretion. The second alert will be either an order entry or open encounter alert, depending on the arm the provider is assigned to.
Study NCT04284553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Different Risks
Description: Risks of the high-risk medications will be framed differently.
Study NCT00677248 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ezetimibe and placebo
Description: Placebo or three different doses of eprotirome added to ezetimibe treatment
Study NCT00677248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eprotirome and ezetimibe
Description: Placebo or three different doses of eprotirome added to ezetimibe treatment
Study NCT03119129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ho'ouna Pono Drug Prevention Curriculum
Description: Ho'ouna Pono is a school-based, culturally grounded drug prevention curriculum tailored to Native Hawaiian and Pacific Islander youth on Hawai'i Island.
Study NCT03686813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil Citrate
Description: Oral sildenafil, 50 mg
Study NCT03686813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo
Study NCT03640273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prapchompoothaweep remedy
Description: Take Prapchompoothaweep remedy capsule at 1,000 mg for 3 times a day before meals.